微小RNA-148a在非小细胞肺癌中的表达及其临床意义

doi:10.3760/cma.j.issn.1673-422X.2016.08.003

摘要/Abstract

摘要： 目的探讨微小RNA-148a(miR-148a)在非小细胞肺癌(NSCLC)中的表达及其与临床病理特征的关系，分析其在临床预后中的作用。方法采用聚合酶链反应（RT-PCR)法检测48例NSCLC组织miR-148a表达水平，以miR-148a表达中位值为界，将48例患者分为两组，即高表达组和低表达组；分析miR-148a表达与患者临床病理特征的关系，采用KaplanMeier法估计生存率并进行单因素分析，Log-rank检验分析miR-148a表达与患者预后的关系。结果 miR-148a在NSCLC癌组织的表达量低于癌旁组织，两组差异具有统计学意义(1.052 ± 0.659∶1.397 ± 0.667，t=2.549，P=0.013)，其表达与肿瘤大小（χ²=4.594，P=0.030）、淋巴结转移（χ²=5.486，P=0.019）、临床分期（χ²=4.090，P=0.043）有关，而与年龄（χ²=0.354，P=0.551）、性别（χ²=2.277，P=0.131）、组织学类型（χ²=0.403，P=0.525）、吸烟史（χ²=0.444，P=0.505）无关。KaplanMeier法分析显示，miR148a低表达患者中位生存期为23.9个月，高表达组患者中位生存期为38.7个月，差异有统计学意义(χ²=4.941，P=0.026)，但是中位无疾病进展生存期分别为21.6个月、29.4个月，差异无统计学意义(χ²=2.168，P=0.141)。结论 miR148a在NSCLC中低表达，miR148a低表达与NSCLC患者恶性病理特征和较差的临床预后密切相关。

关键词: 癌, 非小细胞肺, 微RNAs, 病理状态, 体征和症状, 存活率分析

Abstract: Objective To investigate the expressions of microRNA-148a (miR-148a) in non-small cell lung cancer (NSCLC) tissues and adjacent non-tumor tissues and the relationships with clinicopathologic features, to analyze the roles of miR-148a in evaluating prognosis. MethodsExpression levels of miR-148a in 48 pairs of NSCLC and adjacent non-tumor tissues were detected by quantitative real-time PCR (RT-PCR). The patients were divided into 2 groups according to the median value of miR-148a. The relationships between the expression levels of miR148a and clinicopathological features were analyzed. The survival rate was estimated by KaplanMeier method, and single factor analysis was performed. The relationship between the expression level of miR-148a and prognosis was analyzed by Logrank test. Results miR-148a expression levels were significant down-regulated in NSCLC tissues compared with adjacent non-tumor tissues (1.052 ± 0.659 vs. 1.397 ± 0.667, t=2.549, P=0.013). miR-148a expression level was correlated with tumor size (χ²=4.594, P=0.030), lymph nodes metastasis (χ²=5.486, P=0.019) and clinical stage (χ²=4.090, P=0.043), while it was not correlated with age (χ²=0.354, P=0.551), gender (χ²=2.277, P=0.131), histological type (χ²=0.403, P=0.525) and smoking (χ²=0.444, P=0.505). KaplanMeier analysis revealed a significant correlation between low miR148a expression level and poor overall survival (23.9 months vs. 38.7 months, χ2=4.941, P=0.026), and no significant correlation with progressionfree survival (21.6 months vs. 29.4 months, χ²=2.168, P=0.141). Conclusion Down-regulation of miR-148a is correlated with worse clinicopathological features, which serves an independent marker for poor prognosis in patients with NSCLC.

Key words: Carcinoma, non-small-cell lung, MicroRNAs, Pathological conditions, signs and symptoms, Survival analysis

潘宇凯. 微小RNA-148a在非小细胞肺癌中的表达及其临床意义[J]. 国际肿瘤学杂志, 2016, 43(8): 570-573.

Pan Yukai. Expression and clinical significance of microRNA-148a in patients with non-small cell lung cancer[J]. Journal of International Oncology, 2016, 43(8): 570-573.

参考文献

［1］ Dimou A, Papadimitrakopoulou V. Non-small cell lung cancer beyond biomarkers: the evolving landscape of clinical trial design［J］. J Pers Med, 2014, 4(3): 386-401. DOI: 10.3390/jpm4030386. ［2］ Stella GM, Luisetti M, Pozzi E, et al. Oncogenes in non-small cell lung cancer: emerging connections and novel therapeutic dynamics［J］. Lancet Respir Med, 2013, 1(3): 251-261. DOI: 10.1016/S2213-2600(13)70009-2. ［3］ Vijayvergia NSP, Denlinger CS. Survivorship in non-small cell lung cancer: challenges faced and steps forward［J］. J Natl Compr Canc Netw, 2015, 13(9): 1151-1161. ［4］ Ma R, Wang C, Wang J, et al. miRNA-mRNA interaction network in non-small cell lung cancer［J］. Interdiscip Sci, 2015, In press. DOI: 10.1007/s12539-014-0259-0. ［5］ Wang F, Zhou J, Zhang Y, et al. The value of MicroRNA155 as a prognostic factor for survival in non-small cell lung cancer: a Meta-analysis［J］. PLoS One, 2015, 10(8): e0136889. DOI: 10.1371/journal.pone.0136889. ［6］ Wang R, Chen XF, Shu YQ. Prediction of non-small cell lung cancer metastasis-associated microRNAs using bioinformatics［J］. Am J Cancer Res, 2015, 5(1): 32-51. ［7］ Chen WJ, Zhang EN, Zhong ZK, et al. MicroRNA-153 expression and prognosis in non-small cell lung cancer［J］. Int J Clin Exp Pathol, 2015, 8(7): 8671-8675. ［8］ Cameron L, Solomon B. New treatment options for ALK-rearranged non-small cell lung cancer［J］. Curr Treat Options Oncol, 2015, 16(10): 49. DOI: 10.1007/s11864015-0367-z. ［9］ Joshi P, Jeon YJ, Laganà A, et al. MicroRNA-148a reduces tumorigenesis and increases TRAIL-induced apoptosis in NSCLC［J］. Proc Natl Acad Sci USA, 2015, 112(28): 8650-8655. DOI: 10.1073/pnas.1500886112. ［10］ Sun J, Song Y, Wang Z, et al. Clinical significance of promoter region hypermethylation of microRNA-148a in gastrointestinal cancers［J］. Onco Targets Ther, 2014, 7: 853-863. DOI: 10.2147/OTT.S60888. ［11］ Zhang SL, Liu L. microRNA-148a inhibits hepatocellular carcinoma cell invasion by targeting sphingosine-1phosphate receptor 1［J］. Exp Ther Med, 2015, 9(2): 579-584. DOI: 10.3892/etm.2014.2137. ［12］ Ajdarkosh H, Dadpay M, Yahaghi E, et al. Decrease expression and clinicopathological significance of miR-148a with poor survival in hepatocellular carcinoma tissues［J］. Diagn Pathol, 2015, 10: 135. DOI: 10.1186/s13000-015-0371-4. ［13］ AlvarezGarcia I, Miska EA. MicroRNA functions in animal development and human disease［J］. Development, 2005, 132(21): 4653-4662. ［14］ Feber A, Xi LQ, Luketich JD, et al. MicroRNA expression profiles of esophageal cancer［J］. J Thorac Cardiovasc Surg, 2008, 135(2): 255-260. DOI: 10.1016/j.jtcvs.2007.08.055. ［15］ Selbach M, Schwanh-usser B, Thierfelder N, et al. Widespread changes in protein synthesis induced by microRNAs［J］. Nature, 2008, 455(729): 58-63. DOI: 10.1038/nature07228. ［16］ Heo MJ, Kim YM, Koo JH, et al. microRNA-148a dysregulation discriminates poor prognosis of hepatocellular carcinoma in association with USP4 overexpression［J］. Oncotarget, 2014, 5(9): 2792-2806.

[1]	钱晓涛, 石子宜, 胡格, 吴晓维. Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[2]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[3]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[4]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华. 炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[5]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[6]	顾芳萌, 徐晨阳, 雷大鹏. 人工智能辅助电子喉镜检查在喉癌及喉癌前病变诊治中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(5): 303-307.
[7]	张文馨, 夏泠, 彭晋, 周福祥. 甲胎蛋白升高型胃肝样腺癌1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(5): 312-315.
[8]	王昆, 周中新, 臧其威. 血清TGF-β1、VEGF水平对非小细胞肺癌患者单孔胸腔镜根治术后复发的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 198-203.
[9]	杨毫, 施贵冬, 张程城, 张跃, 张力文, 付茂勇. 信迪利单抗与替雷利珠单抗在进展期食管鳞状细胞癌新辅助治疗中的疗效及安全性对比[J]. 国际肿瘤学杂志, 2024, 51(4): 210-216.
[10]	姚益新, 沈煜霖. 血清SOCS3、TXNIP水平对肝细胞癌TACE治疗预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 217-222.
[11]	胡婷婷, 王越华. 电子鼻与线虫鼻——新型早期癌症筛查工具[J]. 国际肿瘤学杂志, 2024, 51(4): 223-226.
[12]	张栋岩, 王品, 魏秋亚, 邓成伍, 魏相相, 高远飞, 王琛. 索凡替尼靶向联合卡培他滨和奥沙利铂治疗肝内胆管癌术后患者1例及文献复习[J]. 国际肿瘤学杂志, 2024, 51(4): 249-253.
[13]	严爱婷, 王翠竹, 刘春桂, 鲁小敏. 卡瑞利珠单抗与信迪利单抗治疗晚期非小细胞肺癌的临床疗效及安全性分析[J]. 国际肿瘤学杂志, 2024, 51(3): 137-142.
[14]	孙维蔚, 姚学敏, 王鹏健, 王静, 贾敬好. 基于血液学指标探讨免疫治疗晚期非小细胞肺癌预后因素及列线图构建[J]. 国际肿瘤学杂志, 2024, 51(3): 143-150.
[15]	钱晓涛, 石子宜, 胡格. Ⅲ~ⅣA期食管鳞状细胞癌根治性放化疗后行免疫检查点抑制剂维持治疗的真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(3): 151-156.